1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
ASH Bridge Grant is sponsored by American Society of Hematology (ASH). This award is designed to sustain hematology research that was previously submitted to the NIH (R01 mechanism) and received a high score but was not funded. It allows researchers to continue their TLR4 signaling work and generate additional data to respond to NIH reviewers.
Get alerted about grants like this
Save a search for “American Society of Hematology (ASH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ASH Bridge Grant Key Information - Hematology. org American Society of Hematology Early and Mid-Career Investigator Awards and Training Programs ASH Bridge Grant Key Information Agenda for Nematology Research Genome Editing and Gene Therapy Research Support and Funding ASH Bridge Grant Key Information The ASH Bridge Grant is open to ASH members at various career stages who the meet the eligibility requirements.
MDs, PhDs, and MD-PhDs conducting malignant and classical hematology research are encouraged to apply. The ASH Bridge Grant is a $150,000 award designated for ASH members who applied for an NIH R01 grant or equivalent.
The $150,000 ASH Bridge Grant budget allows for the following expenses: Principal Investigator (PI) salary and fringe benefits, travel (if well justified), salary and fringe benefits for research personnel, research supplies, and equipment (up to $10,000 if required and justified by the applicant).
To be considered for an ASH Bridge Grant, the applicant must: Have submitted to the NIH in the past 18 months (as of the application deadline) a hematology-related R01 or R01-equivalent application. This includes investigators applying for their first R01. Please note: The 18-month timeframe begins the date your R01 is reviewed.
Be the Principal Investigator or co-Principal Investigator. Be an ASH member in good standing and plan to maintain membership for the duration of the award term. Not an ASH member yet?
Take the first step . Please note that your membership application may be pending at the application deadline but must be approved by the award activation date. Please be aware of the membership deadlines.
--> Hold a faculty position at an academic institution or the equivalent position at a non-profit research organization. Employees of independent research institutions are eligible to apply if they have a faculty-type appointment and the institution is allowed to independently apply for and receive NIH funding. At the time of award activation, have available no more than $500,000 annually in other research funding.
This amount does not include the applicant's salary/fringe or funding from within the institution or drugs donated by pharmaceutical companies to clinical trials. If the R01 that serves as the base of the Bridge Grant application is funded by the NIH prior to award notification, the applicant must decline the ASH Bridge Grant if awarded.
New in 2025: ASH Bridge Grant Eligibility Expanded Significantly Please take note of three significant changes starting in 2025, as they represent a material change for the 12-year-old program: Individuals who have received a Bridge Grant (that has concluded) are now eligible to apply for funding for a new proposal.
Individuals who had a proposal reviewed but not discussed can now apply under the traditional Bridge Grant Program application, where the applicant can respond to the critiques provided by preliminary reviewers. Individuals who submitted an R01 (or equivalent) grant proposal and have not received a critique can now apply to the ASH Bridge Grant with modified document requirements.
Along with the other required documents, applicants must submit the research strategy of their proposal. This includes grants that may not have yet been reviewed by the NIH due to pauses in study section processes as well as those for which the NIH has not provided a funding decision or critique. These applications will be reviewed separately from traditional applications to the Bridge Grant program.
All other eligibility requirements must be met. Exclusions to Eligibility: Individuals eligible to apply for the ASH Scholar Award are not eligible to apply for the ASH Bridge Grant. If you have never received an R01 or equivalent, have never received an ASH Scholar Award in the Junior Faculty level, or have fewer than 13 years of research experience since your terminal doctoral degree, you might be eligible for the Scholar Award.
The ASH Scholar Award and Bridge Grant have the same deadline so ensure that you are applying to the correct award by contacting [email protected] . Individuals cannot hold two active ASH awards concurrently. If the other ASH award ends before the Bridge Grant begins, you may apply but there can be no overlap.
Applicants must submit proposals to conduct research in hematology. Proposals that fall within any of the categories discussed below are encouraged: Patient-Oriented Clinical Research For additional details on eligible research categories, please consult the Research Definitions page . The Bridge Grant application, as well as all supporting documents outlined below, must be submitted through ASH’s online awards portal.
All applications must include the following: Completed Application Form Completed Budget Supplemental Form Applicant’s NIH Biographical Sketch Institutional Commitment Letter Specific Aims Page from Original R01 First-Year Budget from R01 For more information on required Bridge Grant materials, please see the ASH Bridge Grant Required Documents Checklist Standard Bridge Grant Applications must include the following: Complete Summary Statement from Original R01 (Scores unredacted) Response to Critiques from Original R01 Modified Bridge Grant applications must include the following: If you are having trouble completing your application online, please email [email protected] to request assistance.
An Awards Department staff member will be happy to walk you through the process. Evaluation, Selection, and Notification ASH will perform a preliminary review of the application and all required materials in order to confirm eligibility and completeness. All eligible applications will be reviewed by the Bridge Grant study section based on the scientific merit of proposed research and the applicant's qualifications.
Award winners will be notified in July. If you are selected to receive an award, you will have to affirm that the R01 you submitted to the Bridge Grant has not been funded and that your available resources remain below $500,000.
As a condition of acceptance of the ASH Bridge Grant, it is required that the award recipient cite support from the American Society of Hematology in any publication, poster, or presentation describing research conducted during the period of the award. ASH will pay the award in one installment of $150,000. Awards are non-transferable between individuals or across institutions.
The following expenses are allowable in the $150,000 ASH Bridge Grant budget: PI salary (the percent effort and related salary from the unfunded R01 should be retained) and fringe benefits Travel, if well justified Salary and fringe benefits of research personnel Equipment (up to $10,000 if required for and justified by the applicant) Bridge Grant recipients are required to submit to ASH a final progress report within 60 days of the end of the award period.
ASH will send an email containing the final financial report template and the link to the survey.
Award recipients should be prepared to provide information on, but not limited to, the following topics: Number of extramural grants applied for and obtained during the grant period Number of patents submitted and awarded during the grant period Number of publications submitted and published during the grant period Final financial report describing actual expenses and variances to budget Reallocation, Extension, and Deferral All reallocation, extension, and/or deferral requests and justifications must be sent to [email protected] .
Requests for fund reallocation from one expense category to another must include the dollar amount, which categories are impacted, and a justification as to why the change is necessary. The salary from the ASH award to the investigator must remain within +/- 10% of the original budget proposal submitted with the application. Funded researchers may apply for no-cost extension for up to one year.
Requests to defer commencement of the award for up to three months will be considered. Deferral requests should be noted in the award application, emailed to ASH staff following application but before notification, or emailed within 10 business days of the award notification.
An award will be terminated if the applicant moves to a non-research position, leaves the institution at which they worked at the start of the award, or is dismissed from the institution. For questions about the ASH Bridge Grant, please contact [email protected] or visit the ASH Bridge Grant Frequently Asked Questions page.
Based on current listing details, eligibility includes: ASH members in good standing who are PI or co-PI on an R01 (or equivalent) submitted within 18 months, holding a faculty position at an academic institution, with no more than $500,000 in annual research funding from other sources. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $150,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
ASH Global Research Award is sponsored by American Society of Hematology (ASH). The ASH Global Research Award supports the careers of ASH members who are trainees or early-career investigators based in countries other than the United States or Canada. It fosters an inclusive scientific community by supporting leaders from all regions, including Africa. The award offers flexible funding for a wide array of innovative, project-based, hematology-related applications, including basic, translational, patient-oriented, and outcomes-based research, as well as training opportunities. Projects advancing diagnostic capabilities or therapeutic care delivery for hematological illnesses in developing regions, or addressing high-incidence hematological illnesses in the applicant's home region, are encouraged. The award also supports projects incorporating cross-disciplinary collaborations aimed at enhancing regional scientific and care capabilities for hematologic illnesses.
Visitor Training Program (VTP) is sponsored by American Society of Hematology (ASH). The Visitor Training Program (VTP) is designed to build hematology capacity in low- and middle-income countries by funding hematologists and hematology-related healthcare professionals from these regions to receive up to 12 weeks of training on specific topics or techniques. The training addresses specific hematology needs and is conducted under the supervision and mentorship of an ASH member.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.